Inhibition of the anergic signaling pathway selectively reduces survival in anergic CLL cells. CLL cells displaying an anergic phenotype (pErk1/2+) or a nonanergic phenotype (pErk1/2−) were treated with agents targeting MEK 1/2, ERK 1/2, and NF-AT1c, molecules implicated in the maintenance of anergy. Cells displaying an anergic phenotype showed decreased viability in the presence of these agents compared with nonanergic cells. Adapted from Figure 5 in the article by Apollonio et al that begins on page 3789.